Search results for "Vaccinations"
Latest updates on ACP's priorities, initiatives
ACP Spotlight offers readers a look at ACP's current top priorities and initiatives, as well as highlights from our e-newsletter, ACP Internist Weekly.
https://immattersacp.org/archives/2021/09/latest-updates-on-acps-priorities-initiatives.htm
1 Sep 2021
Regulatory changes for COVID-19 vaccine; data on waning immunity, outpatient therapies
The FDA authorized vaccinating children, the NIH supported concurrent use of flu and COVID-19 shots, and the CDC addressed a fourth dose of COVID-19 vaccine for the immunocompromised. Trials found benefit from a new monoclonal antibody and an old antidepressant for high-risk outpatients.
https://immattersacp.org/weekly/archives/2021/11/02/1.htm
2 Nov 2021
Latest COVID-19 research details local vaccine reactions, ineffective outpatient treatments
A case series described delayed skin reactions to vaccination, and randomized trials indicated that ivermectin, azithromycin, and convalescent plasma didn't help mildly ill patients. Several studies focused on the increase in alcohol use during the pandemic.
https://immattersacp.org/weekly/archives/2021/03/09/1.htm
9 Mar 2021
Latest COVID-19 research looks at vaccines' efficacy, thrombocytopenia risk
Thrombosis with thrombocytopenia is a risk with the Johnson & Johnson (Janssen) vaccine, but not those using mRNA technology, one study found, while other research quantified the vaccines' effectiveness over time. A trial found that monoclonal antibodies reduced progression from asymptomatic to symptomatic infection.
https://immattersacp.org/weekly/archives/2022/01/18/1.htm
18 Jan 2022
Treatment for high-risk COVID-19 patients, vaccine news, research on health messaging
An industry-funded study found benefit with bamlanivimab plus etesevimab for high-risk ambulatory COVID-19 patients, the FDA noted a possible increased risk for Guillain-Barré syndrome with the Johnson & Johnson (Janssen) vaccine, and two studies looked at COVID-19 messaging for minority populations.
https://immattersacp.org/weekly/archives/2021/07/20/1.htm
20 Jul 2021
Concomitant influenza infection associated with worse in-hospital outcomes in heart failure patients
Rates of in-hospital mortality, acute respiratory failure with and without mechanical ventilation, and acute kidney injury with and without dialysis were significantly higher in patients admitted with heart failure and influenza infection compared to admissions for heart failure alone.
https://immattersacp.org/weekly/archives/2019/01/08/4.htm
8 Jan 2019
New research on Pfizer pill, mental disorders after COVID-19, vaccine reactions
A manufacturer-funded trial quantified the effectiveness of nirmatrelvir/ritonavir in outpatients. A retrospective study found veterans had more mental health diagnoses and received more antidepressants, benzodiazepines, and opioids after COVID-19, while two other studies looked at reactions to second and third doses of the vaccines.
https://immattersacp.org/weekly/archives/2022/02/22/1.htm
22 Feb 2022
New research on mixed vaccine boosters, long-term outcomes, omicron severity
A study found mixing and matching of COVID-19 vaccines to be safe and effective, other research showed ongoing symptoms to be common at one year after infection, the CDC analyzed the severity of omicron, and the FDA revised outpatient treatment authorizations.
https://immattersacp.org/weekly/archives/2022/02/01/1.htm
1 Feb 2022
Answers and even more questions on COVID-19 vaccines
In a fourth forum from ACP and Annals of Internal Medicine, infectious disease experts Carlos del Rio, MD, FACP, Paul Sax, MD, and Deborah Cotton, MD, MPH, FACP, discussed COVID-19 vaccines and their implementation, as well as other aspects of the pandemic response.
https://immattersacp.org/weekly/archives/2021/03/30/2.htm
30 Mar 2021
Studies assess responses, reactions to vaccines; long-term effects of COVID-19 infection
Recent COVID-19 vaccine studies showed good response in pregnant women, as well as possible localized rashes from the Moderna vaccine. Analyses of ICU patients and those treated at a post-COVID-19 clinic highlighted the long-term effects of the virus, and a study found that dialysis patients maintained antibodies six months after COVID-19 infection.
https://immattersacp.org/weekly/archives/2021/05/18/1.htm
18 May 2021